Anti-Human CD79B Reference Antibody (Iladatuzumab, RUO)

Description: Iladatuzumab (BS10160) is a research-grade recombinant antibody targeting CD79B. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Humanized
Isotype: IgG1-kappa
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 3.42mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: B-cell-specificglycoproteinB29,CD79B,B-cellantigenreceptorcomplex-associatedproteinbetachain,Ig-beta,B29,Immunoglobulin-associatedB29protein,IGB,CD79b
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: DCDS0780A,MCDS0593A,RO7032005,CAS:1906205-76-2
Background: B-cell antigen receptor complex-associated protein beta chain (CD79B) is a ~26 kDa protein. Required in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation. CD79B is the therapeutic target of polatuzumab vedotin (Polivy).
Note: For research use only. Not suitable for clinical or therapeutic use.